Compare Allbirds Inc (BIRD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Zoetis Inc — how do they compare? Allbirds Inc trades at $2.57 (market cap $30.00M), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 1038× Allbirds Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| BIRD | ZTS | |
|---|---|---|
Market Cap | $30.00M | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $156.76 |
52-Week Low | $2.21 | $71.91 |
Enterprise Value | $48.86M | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD (Smartbird) trades at $2.56, down 0.78% on the day, as the company completes its pivot from footwear to AI infrastructure. Despite negative profitability metrics and declining revenue trends, the stock has shown volatility following recent strategic announcements including a name change and new CEO appointment. Technical indicators show mixed signals with a bullish overall rating but bearish moving averages, while fundamental challenges persist with negative net income margins and cash flow concerns.
The outlook remains speculative as BIRD transitions to AI infrastructure, creating both opportunity and significant risk. While analyst sentiment leans cautious with 79% hold ratings, recent leadership changes and strategic pivot could drive future growth if execution improves. Key risks include sustained cash burn, competitive AI market pressures, and the challenge of establishing credibility in a new industry segment.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
